SECTION C — CHEMISTRY; METALLURGY

- C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE [3]

Note(s) [3, 4, 6]

- 1. This subclass <u>covers</u> both major and minor chemical modifications.
- Group C12P 1/00 covers processes for producing organic compounds not sufficiently identified to be classified in groups C12P 3/00-C12P 37/00. Compounds identified only by their empirical formulae are not considered to be sufficiently identified.
- 3. Attention is drawn to Notes (1) to (3) following the title of class C12.
- 4. If a particular reaction is considered of interest, it is also classified in the relevant chemical compound class, e.g. C07, C08.
- 5. In this subclass:
 - metal or ammonium salts of a compound are classified as that compound;
 - compositions are classified in the relevant compound groups.
- 6. In this subclass, it is desirable to add the indexing codes of subclass C12R.

Subclass index

| BIOSYNTHESIS OF CHEMICAL SUBSTANCES | |
|---|--------------|
| Inorganic compounds | 3/00 |
| Acyclic or carbocyclic organic compounds | 5/00-15/00 |
| peptides or proteins. | 21/00 |
| Carotenes | 23/00 |
| TetracyclinesProstaglandins | 29/00 |
| Prostaglandins | 31/00 |
| Steroids | 33/00 |
| Heterocyclic organic compounds | 17/00 |
| containing saccharide radicals | 19/00 |
| Riboflayin | 25/00 |
| Giberellin | 27/00 |
| Cephalosporin; penicillin | 35/00, 37/00 |
| SEPARATION OF OPTICAL ISOMERS | 41/00 |
| OTHER PROCESSES FOR BIOSYNTHESIS PREPARATIONS | |

| 1/00 | Preparation of compounds or compositions, not |
|------|---|
| | provided for in groups C12P 3/00-C12P 39/00, by |
| | using microorganisms or enzymes; General processes |
| | for the preparation of compounds or compositions by |
| | using microorganisms or enzymes [3, 2006.01] |

- 1/02 by using fungi [3, 2006.01]
- 1/04 by using bacteria **[3, 2006.01]**
- 1/06 by using actinomycetales **[3, 2006.01]**
- 3/00 Preparation of elements or inorganic compounds except carbon dioxide [3, 2006.01]
- 5/00 Preparation of hydrocarbons [3, 2006.01]
- 5/02 acyclic [3, 2006.01]
- 7/00 Preparation of oxygen-containing organic compounds [3, 2006.01]
- 7/02 containing a hydroxy group [3, 2006.01]
- 7/04 • acyclic **[3, 2006.01]**
- 7/06 • Ethanol, i.e. non-beverage [3, 2006.01]

- 7/08 • • produced as by-product or from waste or cellulosic material substrate [3, 2006.01]
- 7/10 • • substrate containing cellulosic material [3, 2006.01]
- 7/12 • • substrate containing sulfite waste liquor or citrus waste [3, 2006.01]
- 7/14 • Multiple stages of fermentation; Multiple types of microorganisms or reuse for microorganisms [3, 2006.01]
- 7/16 • Butanols [3, 2006.01]
- 7/18 • polyhydric [3, 2006.01]
- 7/20 • • Glycerol [3, 2006.01]
- 7/22 • aromatic **[3, 2006.01]**
- 7/24 containing a carbonyl group [3, 2006.01]
- 7/26 • Ketones [3, 2006.01]
- 7/28 • Acetone-containing products **[3, 2006.01]**
- 7/30 • produced from substrate containing inorganic compounds other than water [3, 2006.01]

IPC (2024.01), Section C 1

| 7/32 | • • • produced from substrate containing inorganic nitrogen source [3, 2006.01] | 13/06 | Alanine; Leucine; Isoleucine; Serine; Homoserine [3, 2006.01] |
|----------|---|--------|--|
| 7/34 | • • • produced from substrate containing protein as nitrogen source [3, 2006.01] | 13/08 | • • Lysine; Diaminopimelic acid; Threonine; Valine [3, 2006.01] |
| 7/36 | • • • produced from substrate containing grain or | 13/10 | Citrulline; Arginine; Ornithine [3, 2006.01] |
| | cereal material [3, 2006.01] | 13/12 | • • Methionine; Cysteine; Cystine [3, 2006.01] |
| 7/38 | Cyclopentanone- or cyclopentadione- | 13/14 | Glutamic acid; Glutamine [3, 2006.01] |
| | containing products [3, 2006.01] | 13/16 | using surfactants, fatty acids or fatty acid esters, |
| 7/40 | • containing a carboxyl group [3, 2006.01] | 13/10 | i.e. having at least seven carbon atoms in an |
| 7/42 | Hydroxy carboxylic acids [3, 2006.01] | | unbroken chain bound to a carboxyl group or a |
| 7/44 | • Polycarboxylic acids [3, 2006.01] | | carboxyl ester group [3, 2006.01] |
| 7/46 | Dicarboxylic acids having four or less carbon | 13/18 | • • using biotin or its derivatives [3, 2006.01] |
| | atoms, e.g. fumaric acid, maleic | 13/20 | Aspartic acid; Asparagine [3, 2006.01] |
| | acid [3, 2006.01] | 13/22 | Tryptophan; Tyrosine; Phenylalanine; 3,4- |
| 7/48 | • • • Tricarboxylic acids, e.g. citric acid [3, 2006.01] | | Dihydroxyphenylalanine [3, 2006.01] |
| 7/50 | having keto groups, e.g. 2-ketoglutaric | 13/24 | • • Proline; Hydroxyproline; Histidine [3, 2006.01] |
| | acid [3, 2006.01] | | |
| 7/52 | • • Propionic acid; Butyric acids [3, 2006.01] | 15/00 | Preparation of compounds containing at least three |
| 7/54 | • • Acetic acid [3, 2006.01] | | condensed carbocyclic rings [3, 2006.01] |
| 7/56 | • • Lactic acid [3, 2006.01] | 17/00 | Preparation of heterocyclic carbon compounds with |
| 7/58 | Aldonic, ketoaldonic or saccharic acids (uronic | 17700 | only O, N, S, Se, or Te as ring hetero atoms |
| | acids C12P 19/00) [3, 2006.01] | | (C12P 13/04-C12P 13/24 take precedence) [3, 2006.01] |
| 7/60 | • • • 2-Ketogulonic acid [3, 2006.01] | 17/02 | • Oxygen as only ring hetero atoms [3, 2006.01] |
| 7/62 | Carboxylic acid esters [3, 2006.01, 2022.01] | 17/04 | containing a five-membered hetero ring, e.g. |
| 7/625 | • • Polyesters of hydroxy carboxylic acids [2022.01] | | griseofulvin [3, 2006.01] |
| 7/64 | • Fats; Fatty oils; Ester-type waxes; Higher fatty acids, | 17/06 | containing a six-membered hetero ring, e.g. |
| | i.e. having at least seven carbon atoms in an | | fluorescein [3, 2006.01] |
| | unbroken chain bound to a carboxyl group; Oxidised | 17/08 | containing a hetero ring of at least seven ring |
| 7/6/00 | oils or fats [3, 2006.01, 2022.01] | | members, e.g. zearalenone, macrolide |
| | • Fatty acids [2022.01] | 45/40 | aglycons [3, 2006.01] |
| | • • by hydrolysis of fatty acid esters [2022.01]• • Polyunsaturated fatty acids [PUFA], i.e. having | 17/10 | Nitrogen as only ring hetero atom [3, 2006.01] |
| //042/ | two or more double bonds in their | 17/12 | • • containing a six-membered hetero |
| | backbone [2022.01] | 17/14 | ring [3, 2006.01] • Nitrogen or oxygen as hetero atom and at least one |
| 7/6431 | • • • Linoleic acids [18:2[n-6]] [2022.01] | 1//14 | other diverse hetero ring atom in the same |
| | • • • Eicosapentaenoic acids [EPA] [2022.01] | | ring [3, 2006.01] |
| | • • • Docosahexenoic acids [DHA] [2022.01] | 17/16 | containing two or more hetero rings [3, 2006.01] |
| | • • Fatty acid esters [2022.01] | 17/18 | containing at least two hetero rings condensed among |
| | • • • Glycerides [2022.01] | | themselves or condensed with a common carbocyclic |
| | • • • • by esterification [2022.01] | | ring system, e.g. rifamycin [3, 2006.01] |
| | • • • by transesterification, e.g. interesterification, | 10/00 | Proceedings for the characteristic and the |
| | ester interchange, alcoholysis or | 19/00 | Preparation of compounds containing saccharide radicals (ketoaldonic acids C12P 7/58) [3, 2006.01] |
| | acidolysis [2022.01] | | radicals (Retoditionic delus C12F //30) [3, 2000.01] |
| 7/6463 | • • • obtained from glyceride producing | | <u>Note(s) [3]</u> |
| | microorganisms, e.g. single cell | | Attention is drawn to Note (3) following the title of |
| = /0.4=0 | oil [2022.01] | | subclass C07H, which defines the expression |
| //64/2 | • • • containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more | | "saccharide radical". |
| | double bonds in their backbone [2022.01] | 19/02 | Monosaccharides [3, 2006.01] |
| 7/6/181 | Phosphoglycerides (phosphoglycerides) | 19/04 | Polysaccharides, i.e. compounds containing more |
| 770401 | having carboxylic acids with less than seven | | than five saccharide radicals attached to each other |
| | carbon atoms C12P 7/62) [2022.01] | 10.406 | by glycosidic bonds [3, 2006.01] |
| 7/649 | • • • Biodiesel, i.e. fatty acid alkyl esters [2022.01] | 19/06 | • • Xanthan, i.e. Xanthomonas-type |
| 7/66 | • containing the quinoid structure [3, 2006.01] | 19/08 | heteropolysaccharides [3, 2006.01] • Dextran [3, 2006.01] |
| | | 19/08 | • • Pullulan [3, 2006.01] |
| 9/00 | Preparation of organic compounds containing a | 19/10 | • Disaccharides [3, 2006.01] |
| | metal or atom other than H, N, C, O, S, or halogen [3, 2006.01] | 19/12 | • produced by the action of a carbohydrase, e.g. by |
| | 10006CII [0, 2000.01] | 13/14 | alpha-amylase [3, 2006.01] |
| 11/00 | Preparation of sulfur-containing organic | 19/16 | produced by the action of an alpha-1, 6-glucosidase, |
| | compounds [3, 2006.01] | | e.g. amylose, debranched amylopectin [3, 2006.01] |
| 10/00 | Description of mission of the second of the | 19/18 | produced by the action of a glycosyl transferase, e.g. |
| 13/00 | Preparation of nitrogen-containing organic | | alpha-, beta- or gamma-cyclodextrins [3, 2006.01] |
| 13/02 | compounds [3, 2006.01]Amides, e.g. chloramphenicol [3, 2006.01] | 19/20 | produced by the action of an exo-1, 4 alpha- |
| 13/02 | • Alpha- or beta-amino acids [3, 2006.01] | | glucosidase, e.g. dextrose [3, 2006.01] |
| 10/04 | rapha- or octa-annio actus [0, 2000.01] | | |

| 19/22 | produced by the action of a beta-amylase, e.g. maltose [3, 2006.01] | 21/04 | • • Cyclic or bridged peptides or polypeptides, e.g. bacitracin [3, 2006.01] |
|----------------|---|----------------|---|
| 19/24 | produced by the action of an isomerase, e.g. fructose [3, 2006.01] | | Note(s) [2020.01] |
| 19/26 | Preparation of nitrogen-containing carbohydrates [3, 2006.01] | | Cyclic or bridged peptides or polypeptides cyclised only by —S—S— bonds are classified in group C12P 21/02 only. |
| 19/28 19/30 | • N-glycosides [3, 2006.01] | 21/06 | produced by the hydrolysis of a peptide bond, e.g. |
| 19/30 | • Nucleotides [3, 2006.01]• having a condensed ring system containing a | | hydrolysate products [3, 2006.01] |
| 15, 52 | six-membered ring having two nitrogen atoms in the same-ring, e.g. purine | 21/08 | Monoclonal antibodies [5, 2006.01] |
| 19/34 | nucleotides, nicotineamide-adenine dinucleotide [3, 2006.01] • • • Polynucleotides, e.g. nucleic acids, | 23/00 | Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double |
| | oligoribonucleotides [3, 2006.01] | | bonds, e.g. carotenes (containing hetero-rings C12P 17/00) [3, 2006.01] |
| 19/36 | • • • Dinucleotides, e.g. nicotineamide-adenine dinucleotide phosphate [3, 2006.01] | 25/00 | Dropagation of compounds containing alloyaging or |
| 19/38 | • • • Nucleosides [3, 2006.01] | 23/00 | Preparation of compounds containing alloxazine or isoalloxazine nucleus, e.g. riboflavin [3, 2006.01] |
| 19/40 | having a condensed ring system containing a | 2= /22 | - |
| | six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides [3, 2006.01] | 27/00 | Preparation of compounds containing a gibbane ring system, e.g. gibberellin [3, 2006.01] |
| 19/42 | Cobalamins, i.e. vitamin B₁₂, LLD | 29/00 | Preparation of compounds containing a naphthacene |
| 10/11 | factor [3, 2006.01] | | ring system, e.g. tetracycline (C12P 19/00 takes precedence) [3, 2006.01] |
| 19/44 | Preparation of O-glycosides, e.g. glucosides [3, 2006.01] | 24/22 | • |
| 19/46 | having an oxygen atom of the saccharide radical | 31/00 | Preparation of compounds containing a five- membered ring having two side-chains in ortho |
| | bound to a cyclohexyl radical, e.g. | | position to each other, and having at least one oxygen |
| 19/48 | kasugamycin [3, 2006.01]the cyclohexyl radical being substituted by two | | atom directly bound to the ring in ortho position to |
| 13/40 | or more nitrogen atoms, e.g. destomycin, | | one of the side-chains, one side-chain containing, not directly bound to the ring, a carbon atom having |
| | neamin [3, 2006.01] | | three bonds to hetero atoms with at the most one |
| 19/50 | • • • having two saccharide radicals bound through only oxygen to adjacent ring carbon | | bond to halogen, and the other side-chain having at least one oxygen atom bound in gamma-position to |
| | atoms of the cyclohexyl radical, e.g. | | the ring, e.g. prostaglandins [3, 2006.01] |
| | ambutyrosin, ribostamycin [3, 2006.01] | 22 /00 | |
| 19/52 | • • • • containing three or more saccharide radicals, e.g. neomycin, | 33/00 | Preparation of steroids [3, 2006.01] |
| | lividomycin [3, 2006.01] | | Note(s) [3] |
| 19/54 | • • • the cyclohexyl radical being bound directly to a | | Attention is drawn to Note (1) following the title of |
| | >N-C-N< | | subclass C07J, which explains what is covered by the term "steroids". |
| | nitrogen atom of two or more N radicals, e.g. streptomycin [3, 2006.01] | | Note(s) [3] |
| 19/56 | having an oxygen atom of the saccharide radical | | In groups C12P 33/02-C12P 33/20, the following terms |
| | directly bound to a condensed ring system having | | are used with the meaning indicated: |
| | three or more carbocyclic rings, e.g. daunomycin, adriamycin [3, 2006.01] | | "acting", "forming", "hydroxylating", |
| 19/58 | having an oxygen atom of the saccharide radical | | "dehydroxylating" or "dehydrogenating" means the action of a microorganism or |
| | directly bound through only acyclic carbon atoms | | enzyme rather than other chemical action. |
| | to a non-saccharide heterocyclic ring, e.g. bleomycin, phleomycin [3, 2006.01] | 33/02 | • Dehydrogenating; Dehydroxylating [3, 2006.01] |
| 19/60 | having an oxygen of the saccharide radical directly | 33/04 | • • Forming an aryl ring from A ring [3, 2006.01] |
| | bound to a non-saccharide heterocyclic ring or a | 33/06 33/08 | Hydroxylating [3, 2006.01]at 11 position [3, 2006.01] |
| | condensed ring system containing a non- saccharide heterocyclic ring, e.g. coumermycin, | 33/10 | • • at 11alpha-position [3, 2006.01] |
| | novobiocin [3, 2006.01] | 33/12 | • Acting on D ring [3, 2006.01] |
| 19/62 | • • the hetero ring having eight or more ring | 33/14 | • • Hydroxylating at 16 position [3, 2006.01] |
| | members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, | 33/16 | • • Acting at 17 position [3, 2006.01] |
| | nystatin [3, 2006.01] | 33/18 33/20 | • Hydroxylating at 17 position [3, 2006.01] • containing heterocyclic rings [3, 2006.01] |
| 19/64 | Preparation of S-glycosides, e.g. | JJ/ 2U | containing neterocyclic rings [3, 2000.01] |
| | lincomycin [3, 2006.01] | 35/00 | Preparation of compounds having a 5-thia-1- |
| 21/00 | Preparation of peptides or proteins (single-cell | | azabicyclo [4.2.0] octane ring system, e.g. cephalosporin [3, 2006.01] |
| | protein C12N 1/00) [3, 2006.01] | 35/02 | by desacylation of the substituent in the 7 |
| 21/02 | having a known sequence of two or more amino acids, e.g. glutathione [3, 2006.01] | | position [3, 2006.01] |
| | acido, c.g. giutamione [0, 2000.01] | | |

IPC (2024.01), Section C 3

C12P

| 35/04 35/06 35/08 | by acylation of the substituent in the 7 position [3, 2006.01] Cephalosporin C; Derivatives thereof [3, 2006.01] disubstituted in the 7 position [3, 2006.01] | 37/04 37/06 | by acylation of the substituent in the 6 position [3, 2006.01] by desacylation of the substituent in the 6 position [3, 2006.01] |
|-------------------------|---|----------------|---|
| 37/00 | Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin [3, 2006.01] | 39/00 | Processes involving microorganisms of different genera in the same process, simultaneously [3, 2006.01] |
| 37/02 | in presence of phenylacetic acid or phenylacetamide or their derivatives [3, 2006.01] | 41/00 | Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture [4, 2006.01] |

4 IPC (2024.01), Section C